Skip to main content
REGENA PEPTIDES

Research Library

SM Research: GLP-1 Evidence and Outcomes

SM is a GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and cardiovascular risk reduction in people with obesity and established cardiovascular disease. The STEP and SELECT programmes gave the class its first hard-outcome evidence, moving it beyond weight and glucose endpoints.

Summary

SM is a GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and cardiovascular risk reduction in people with obesity and established cardiovascular disease. The STEP and SELECT programmes gave the class its first hard-outcome evidence, moving it beyond weight and glucose endpoints.

Last reviewed 2026-09-01

What it is

SM is an analogue of human GLP-1 with 94% sequence homology, modified at position 8 to resist DPP-4 degradation and carrying a C18 fatty diacid linker that binds albumin, giving a half-life of about one week.

A later-generation GLP-1 analogue following liraglutide, extensively described in the peer-reviewed literature.

Synthetic analogue of the endogenous incretin hormone GLP-1, which is secreted by intestinal L-cells after eating.

Outcome details are reported in the cited peer-reviewed literature.

How it works

In plain terms

SM mimics a gut hormone released after eating. It tells the brain that you are full, slows how fast the stomach empties, and helps the pancreas release insulin only when glucose is high.

Technical detail

GLP-1 receptor agonism in the hypothalamic arcuate nucleus and area postrema reduces energy intake; peripheral effects include delayed gastric emptying, glucose-dependent insulin secretion and glucagon suppression. GLP-1 receptors are also present on cardiac, renal and vascular tissue, and anti-inflammatory and endothelial effects are proposed as contributors to the cardiovascular outcome findings, independent of weight change.

Pathways involved

  • Hypothalamic and area postrema appetite regulation
  • Delayed gastric emptying
  • Glucose-dependent insulin secretion, glucagon suppression
  • Vascular and renal GLP-1 receptor signalling

Current research

Laboratory research

Receptor binding, albumin affinity and DPP-4 resistance are fully characterised; the pharmacokinetic design is textbook.

Animal research

Rodent studies established appetite and glycaemic effects, and produced the thyroid C-cell tumour findings that underpin the class boxed warning.

Human research

FLOW reported kidney outcome benefits in type 2 diabetes with chronic kidney disease. Trials in heart failure with preserved ejection fraction and in metabolic dysfunction-associated steatohepatitis have also reported positive findings.

Ongoing research

Programmes in Alzheimer's disease, addiction-related endpoints and peripheral arterial disease are the most watched current threads.

What is being investigated

  • Chronic weight management (approved)
  • Type 2 diabetes glycaemic control (approved)
  • Cardiovascular event reduction (approved in several markets)
  • Chronic kidney disease progression
  • Metabolic dysfunction-associated steatohepatitis
  • Neurodegenerative and addiction endpoints (exploratory)

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

  • Gastrointestinal adverse events are common, especially during dose escalation
  • Boxed warning for thyroid C-cell tumours from rodent data; contraindicated with medullary thyroid carcinoma history or MEN2
  • Outcome details are reported in the cited peer-reviewed literature.
  • Rare reports of non-arteritic anterior ischaemic optic neuropathy are under regulatory review
  • Outcome details are reported in the cited peer-reviewed literature.

Evidence ratings

Laboratory studies

Strong

Mechanism and pharmacokinetics fully characterised.

Animal studies

Strong

Extensive; also the source of the C-cell tumour signal.

Human studies

Strong

Large Phase 3 programme plus hard cardiovascular outcome data.

Long-term safety

Moderate

Multi-year randomised data; post-marketing surveillance ongoing.

Comparisons

TZ vs SM

Cagrilintide vs SM

References

  1. [1]STEP-1 weight management trial — PubMed / NEJM, 2021
  2. [2]SELECT cardiovascular outcomes — PubMed / NEJM, 2023
  3. [3]FLOW kidney outcomes — PubMed / NEJM, 2024
  4. [4]Registered SM trials — ClinicalTrials.gov, current
  5. Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is SM?+

A GLP-1 receptor agonist — a modified analogue of the human incretin hormone GLP-1 — with a one-week half-life.

Is SM FDA approved?+

Yes, for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in adults with obesity and established cardiovascular disease.

Is SM a peptide?+

Yes. SM is a 31–amino-acid peptide analogue with a fatty acid side chain.

How does SM differ from TZ?+

SM acts on one receptor (GLP-1); TZ acts on two (GLP-1 and GIP) and produced larger reductions in head-to-head trials.

Does SM work orally?+

Yes, in a formulation using the absorption enhancer SNAC, though bioavailability is low and dosing requirements are strict.

What happens when you stop?+

The STEP-1 extension found participants regained about two-thirds of lost weight within a year of stopping.

Are the eye safety reports confirmed?+

Rare cases of non-arteritic anterior ischaemic optic neuropathy have been reported and reviewed by regulators; a causal relationship has not been established.

Share

Continue your research

TZ research

Cagrilintide research

Incretin side effects

More research reading

Research supply · Independent documentation and customer feedback

We accept · Multiple secure payment methods

  • Bank Transfer
  • Card via Revolut